Hypoglycemic Activity and Safety Assessment of Pediococcus acidilactici Strain DNH16 in Experimental Type 2 Diabetes Mellitus Rats Induced with Streptozotocin
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) cases tend to rise throughout the year in all parts of the world. The α-glucosidase inhibitors are frequently used to both prevent and treat T2DM. This α-glucosidase inhibitor activity is seen in some probiotic species, and a certain strain of Pediococcus acidilactici exhibits promising characteristics as an α-glucosidase inhibitor. This study was conducted to assess the hypoglycemic activity and safety of P. acidilactici strain DNH16 (PADNH16) in experimental rats with T2DM induced by streptozotocin.
METHODS: The experiment was conducted in vivo using Wistar rats. Acarbose was employed as a positive control, and Lactobacillus casei was used as a comparative. For 24 days, post-prandial blood glucose levels were assessed every 3 days, followed by serum biochemical levels measurement of liver, kidney, and lipid profiles. The pancreas was histopathologically examined utilizing the Hematoxyline-Eosin staining procedure.
RESULTS: Administration of PADNH16 to T2DM rats lowered post-prandial blood glucose levels and gave hypoglycemic benefits comparable to acarbose and commercial probiotics. PADNH16 dosing did not affect serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), urea, or creatinine levels, showing that PADNH16 was not hazardous to liver or kidney function. The lipid profile assessment revealed that the values, including high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, were comparable to the control group. The pancreatic histopathology revealed that injection of PADNH16 caused no alterations to pancreatic β cells.
CONCLUSION: P. acidilactici isolate DNH16 has a hypoglycemic effect on T2DM rats, but does not affect liver function enzymes, kidneys, lipid profiles and does not provide significant changes in pancreatic β cells.
KEYWORDS: diabetes mellitus, inhibitor α-glucosidase, Pediococcus acidilactici strain DNH16
Full Text:
PDFReferences
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J. 2012; 27(4): 269–73, CrossRef.
Hussain H, Nazir M, Saleem M, Al-Harrasi A, Elizbit, Green IR. Fruitful decade of fungal metabolites as anti-diabetic agents from 2010 to 2019: Emphasis on α-glucosidase inhibitors. Phytochem Rev. 2021; 20: 145–79, CrossRef.
Tanoey J, Becher H. Diabetes prevalence and risk factors of early-onset adult diabetes: Results from the Indonesian family life survey. Glob Health Action. 2021; 14(1): 2001144, CrossRef.
Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012; 8(5): 899–906, CrossRef.
Ren F, Ji N, Zhu Y. Research progress of α-glucosidase inhibitors produced by microorganisms and their applications. Foods. 2023; 12(18): 3344, CrossRef.
Van De Laar FA, Lucassen PLBJ, Akkermans RP, Van De Lisdonk EH, Rutten GEHM, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; 2005(2): CD003639, CrossRef.
Fijan S. Microorganisms with claimed probiotic properties: An overview of recent literature. Int J Environ Res Public Health. 2014; 11(5): 4745–67, CrossRef.
Muganga L, Liu X, Tian F, Zhao J, Zhang H, Chen W. Screening for lactic acid bacteria based on antihyperglycaemic and probiotic potential and application in synbiotic set yoghurt. J Funct Foods. 2015; 16: 125–36, CrossRef.
Frediansyah A, Suryani, Nurhayati R, Miftakhussolikhah, Sholihah J. Lactobacillus pentosus isolated from Muntingia calabura shows inhibition activity toward alpha-glucosidase and alpha-amylase in intra and extracellular level. IOP Conf Ser Earth Environ Sci. 2019; 251(1): 012045, CrossRef.
Nurhayati R, Miftakhussolikhah, Frediansyah A, Rachmah DL. Lactic acid bacteria producing inhibitor of alpha glucosidase isolated from ganyong (Canna edulis) and kimpul (Xanthosoma sagittifolium). IOP Conf Ser Earth Environ Sci. 2017; 101(1): 012009, CrossRef.
Hutahaean AJN, Silalahi J, Suryanto D, Satria D. Characterisation of lactic acid bacteria from Dengke Naniura of common carp (Cyprinus carpio) with α-glucosidase inhibitory activity. Open Access Maced J Med Sci. 2019; 7(22): 3794–8, CrossRef.
Fachrial E, Anggraini S, Harmileni, Saryono, Nugroho TT. Inhibitor α-glucosidase activity of Pediococcus acidilactici DNH16 isolated from Dali ni Horbo, a traditional food from North Sumatra, Indonesia. Biodiversitas. 2023; 24(2): 958–65, article.
Bamgbose T, Sinha S, Abdullahi IO, Inabo HI, Bello M, Kori LD, et al. Identification of predominant lactic acid bacteria associated with kunun-zaki and kindirmo a traditional fermented food of Nigeria. Curr Top Lact Acid Bact Probiotics. 2022; 8(1): 17–31, CrossRef.
Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res. 2008; 2008: 704045, CrossRef.
Kumar M, Dandapat S, Prasad Sinha M, Kumar A, Raipat BS. Different blood collection methods from rats: A review. Balneo Res J. 2017; 8(2): 46–50, CrossRef.
Widyatmaka MN, Ismail A. The effect of antlion (Myrmeleon sp.) extract towards histopathology image of pancreas in diabetic mice. Sains Med. 2021; 11(2): 48, CrossRef.
Damasceno DC, Netto AO, Iessi IL, Gallego FQ, Corvino SB, Dallaqua B, et al. Streptozotocin-induced diabetes models: Pathophysiological mechanisms and fetal outcomes. Biomed Res Int. 2014; 2014: 819065, CrossRef.
Altay M. Acarbose is again on the stage. World J Diabetes. 2022; 13(1): 1–4, CrossRef.
Bobga PT, Fossi BT, Taiwe GS, Nkanpira KT, Yolande NE, Ngwa FA, et al. Evaluation of the anti-diabetic potential of probiotic Lactobacillus fermentum (PRI 29) isolated from cameroonian fermented cow milk in alloxan induced diabetes type-1 mice model. Saudi J Pathol Microbiol. 2022; 7(10): 381–93, CrossRef.
Manaer T, Yu L, Zhang Y, Xiao XJ, Nabi XH. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin. J Ethnopharmacol. 2015; 169: 269–74, CrossRef.
Widodo W, Kusumaningrum HRP, Wihadmadyatami H, Wicaksana AL. Milk fermented with Pediococcus acidilactici strain BE improves high blood glucose levels and pancreatic beta-cell function in diabetic rats. Food Sci Anim Resour. 2023; 43(1): 170–83, CrossRef.
Yavorov‐dayliev D, Milagro FI, Ayo J, Oneca M, Aranaz P. Pediococcus acidilactici CECT9879 (pA1c) counteracts the effect of a high‐glucose exposure in C. elegans by affecting the insulin signaling pathway (IIS). Int J Mol Sci. 2022; 23(5): 2689, CrossRef.
Cai T, Wu H, Qin J, Qiao J, Yang Y, Wu Y, et al. In vitro evaluation by PCA and AHP of potential antidiabetic properties of lactic acid bacteria isolated from traditional fermented food. LWT - Food Sci Technol. 2019; 115(2): 108455, CrossRef.
Farida E, Nuraida L, Giriwono PE, Jenie BSL. Lactobacillus rhamnosus reduces blood glucose level through downregulation of gluconeogenesis gene expression in streptozotocin-induced diabetic rats. Int J Food Sci. 2020; 2020: 6108575, CrossRef.
Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: A multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020; 8(1): e001319, CrossRef.
Murti LNW, Ayumuyas NP, Suharjono. Probiotics usage as therapy on diabetes mellitus type II: A literature review. Pharm J Indones. 2019; 4(2): 73–7, article.
Kumar P, Ranawade AV, Kumar NG. Potential probiotic Escherichia coli 16 harboring the Vitreoscilla hemoglobin gene improves gastrointestinal tract colonization and ameliorates carbon tetrachloride induced hepatotoxicity in rats. Biomed Res Int. 2014: 2014: 213574, CrossRef.
Pandya D, Nagrajappa AK, Ravi KS. Assessment and correlation of urea and creatinine levels in saliva and serum of patients with chronic kidney disease, diabetes and hypertension: A research study. J Clin Diagnostic Res. 2016; 10(10): ZC58–62, CrossRef.
Alexopulos AS, Qamar A, Hutchins K, Crowley MJ, Batch BC, Guyton JR. Triglycerides: Emerging targets in diabetes care? Review of moderate hypertriglyceridemia in diabetes. Curr Diab Rep. 2019; 19(4): 13, CrossRef.
Ahmad MF, Haidar MA, Naseem N, Ahsan H, Siddiqui WA. Hypoglycaemic, hypolipidaemic and antioxidant properties of Celastrus paniculatus seed extract in STZ-induced diabetic rats. Mol Cell Biomed Sci. 2023; 7(1): 10–7, CrossRef.
Naqvi S, Naveed S, Ali Z, Ahmad SM, Asadullah Khan R, Raj H, et al. Correlation between glycated hemoglobin and triglyceride level in type 2 diabetes mellitus. Cureus. 2017; 9(6): e1347, CrossRef.
Khan NU, Qazi NG, Khan AU, Ali F, Hassan SSU, Bungau S. Antidiabetic activity of Brucine in streptozotocin-induced rats: In silico, in vitro, and in vivo studies. ACS Omega. 2022; 7(50): 46358–70, CrossRef.
Sariyanti M, Andita TA, Erlinawati ND, Yunita E, Nasution AA, Sari K, et al. Probiotic Lactobacillus acidophilus FNCC 0051 improves pancreatic histopathology in streptozotocin-induced type-1 diabetes mellitus rats. Indones Biomed J. 2022; 14(4): 329–441, CrossRef.
Kwok KO, Fries LR, Silva-Zolezzi I, Thakkar SK, Iroz A, Blanchard C. Effects of probiotic intervention on markers of inflammation and health outcomes in women of reproductive age and their children. Front Nutr. 2022; 9: 889040, CrossRef.
DOI: https://doi.org/10.18585/inabj.v16i1.2781
Copyright (c) 2024 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
